Vericel (VCEL) Set to Announce Earnings on Wednesday

Vericel (NASDAQ:VCEL) is set to issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Vericel has set its FY 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.08. The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $64.28 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The business’s revenue was up 23.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.12 EPS. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Vericel Stock Performance

NASDAQ:VCEL opened at $46.94 on Tuesday. The company has a fifty day moving average of $47.21 and a two-hundred day moving average of $41.45. Vericel has a fifty-two week low of $30.18 and a fifty-two week high of $53.05. The stock has a market capitalization of $2.27 billion, a PE ratio of -521.50 and a beta of 1.74.

Insider Activity

In related news, SVP Sean C. Flynn sold 8,115 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $45.33, for a total value of $367,852.95. Following the completion of the transaction, the senior vice president now directly owns 167 shares in the company, valued at $7,570.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Vericel news, SVP Sean C. Flynn sold 8,115 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $45.33, for a total value of $367,852.95. Following the transaction, the senior vice president now owns 167 shares of the company’s stock, valued at $7,570.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert L. Md Zerbe sold 3,278 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $51.57, for a total transaction of $169,046.46. Following the completion of the sale, the director now directly owns 23,395 shares in the company, valued at $1,206,480.15. The disclosure for this sale can be found here. Insiders sold a total of 54,267 shares of company stock valued at $2,450,996 in the last 90 days. Company insiders own 7.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on VCEL. TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a research note on Monday, January 29th. Truist Financial reissued a “buy” rating and issued a $54.00 price objective on shares of Vericel in a research note on Tuesday, March 26th. Finally, HC Wainwright increased their target price on shares of Vericel from $46.00 to $53.00 and gave the company a “buy” rating in a research report on Friday, March 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.40.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.